Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 10/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28354520 | 0.85 | GRM4 (0.44) | GRM4SCN9A | |
| SCHEMBL28354716 | 0.80 | GRM4 (0.41) | GRM4SCN9ACNR2 | |
| SCHEMBL20595203 | 0.79 | CLK4 (0.43) | — | |
| SCHEMBL30450229 | 0.78 | SCN9A (0.55) | GRM4SORT1SCN9A | |
| SCHEMBL20596679 | 0.78 | SCN9A (0.55) | GRM4SORT1SCN9A | |
| SCHEMBL22809609 | 0.78 | PRKCH (0.42) | GRM4SCN9A | |
| Hydrochloric Acid SCHEMBL20595188 | 0.77 | PRKCH (0.41) | GRM4SCN9A | |
| Hydrochloric Acid SCHEMBL30449677 | 0.77 | PRKCH (0.41) | GRM4SCN9A | |
| SCHEMBL17164105 | 0.71 | RHOC (0.56) | — | |
| SCHEMBL22559424 | 0.68 | SCN5A (0.52) | GRM4SCN9ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | GRM4 1049/4885SORT1 3673/4885SCN9A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.